ArticleFrontiers in immunology2025
Modified EASIX score on day 7 predicts survival and non-relapse mortality in pediatric acute leukemia undergoing haploidentical stem cell transplantation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time-Dependent Prognostic Value of the mEASIX Score in Patients with Myelodysplastic Syndromes.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Endothelial Activation and Stress Index (EASIX) has been validated in adult hematopoietic stem cell transplantation (HSCT) recipients as a predictor of overall survival (OS), non-relapse mortality (NRM), and endothelial-related complications. However, the prognostic significance in children receiving haploidentical donor (HID) transplantation based on myeloablative conditioning (MAC) is still uncertain. Method: Pediatric leukemia patients who underwent HID transplantation at the Children's Hospital of Soochow University between January 2020 and December 2024 were retrospectively reviewed. Based on transplantation dates, patients were assigned to training and validation cohorts. EASIX (lactate dehydrogenase (U/L) × creatinine (mg/dL)/platelet (10 Results: In the training cohort, we stratified patients into groups with high or low D7-m-EASIX expressions, based on the optimal cutoff of 4.1 identified using maximally selected log-rank statistics. In the training cohort, D7-m-EASIX >4.1 was an independent predictor of overall survival (OS, HR:2.35, P = 0.013), relapse-free survival (RFS, HR:1.85, P = 0.047), NRM (HR:3.32, P = 0.009), and was associated with II-IV acute graft-versus-host disease (aGVHD, HR:2.16, P = 0.003) in multivariate analysis. The validation cohort supported these results (OS [HR:6.56, P = 0.005], RFS [HR:3.20, P = 0.030], NRM [HR:5.32, P = 0.040], and II-IV aGVHD [HR:2.57, P = 0.008]). Conclusion: D7-m-EASIX is a simple and valuable prognostic biomarker for pediatric leukemia patients undergoing HID transplantation based on MAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.